54069 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 12
00:54 UTC
|
BBIO
BridgeBio Pharma
|
◎ Target | Geoff Meacham ★★★☆☆ #1105 | Buy | $101.00→ $104.00+3.0% |
|
Aug 12
00:54 UTC
|
BBIO
BridgeBio Pharma
|
◎ Target | Sean Laaman ★★★☆☆ #1057 | Overweight | $98.00→ $97.00-1.0% |
|
Aug 12
00:54 UTC
|
BBIO
BridgeBio Pharma
|
◎ Target | Tyler Van Buren ★★☆☆☆ #2468 | Buy | $95.00→ $110.00+15.8% |
|
Aug 12
00:54 UTC
|
BBIO
BridgeBio Pharma
|
◎ Target | Biren Amin ★☆☆☆☆ #3102 | Overweight | $111.00→ $115.00+3.6% |
|
Aug 12
00:54 UTC
|
BATS
British American Tobacco
|
◎ Target | firm only | Underperform | GBX 3,600→ GBX 3,800+5.6% |
|
Aug 12
00:54 UTC
|
B
Barrick Mining
|
◎ Target | firm only | Buy | $61.00→ $59.00-3.3% |
|
Aug 12
00:54 UTC
|
B
Barrick Mining
|
◎ Target | Lawson Winder ★★☆☆☆ #2282 | Buy | $56.00→ $54.00-3.6% |
|
Aug 12
00:54 UTC
|
AXSM
Axsome Therapeutics
|
◎ Target | Yatin Suneja ★☆☆☆☆ #2924 | Buy | $260.00→ $275.00+5.8% |
|
Aug 12
00:54 UTC
|
AXSM
Axsome Therapeutics
|
◎ Target | Benjamin Burnett ★★★☆☆ #1834 | Overweight | $255.00→ $256.00+0.4% |
|
Aug 12
00:54 UTC
|
AXSM
Axsome Therapeutics
|
◎ Target | Leonid Timashev ★★★☆☆ #1417 | Outperform | $304.00→ $297.00-2.3% |
|
Aug 12
00:54 UTC
|
AXSM
Axsome Therapeutics
|
◎ Target | Sean Laaman ★★★☆☆ #1057 | Equal Weight | $242.00→ $251.00+3.7% |
|
Aug 12
00:54 UTC
|
AXSM
Axsome Therapeutics
|
◎ Target | Ami Fadia ★★★☆☆ #2060 | Buy | $267.00→ $268.00+0.4% |
|
Aug 12
00:54 UTC
|
AURA
Aura Biosciences
|
◎ Target | Andres Y. Maldonado ★★☆☆☆ #2639 | Buy | $24.00→ $18.00-25.0% |
|
Aug 12
00:54 UTC
|
ASTS
AST SpaceMobile
|
◎ Target | Christopher Schoell not yet tracked | Neutral | $80.00→ $78.00-2.5% |
|
Aug 12
00:54 UTC
|
ASTS
AST SpaceMobile
|
◎ Target | Alexander Potter ★☆☆☆☆ #3127 | Overweight | $100.00→ $98.00-2.0% |
|
Aug 12
00:54 UTC
|
ASTS
AST SpaceMobile
|
◎ Target | Colin Canfield ★★☆☆☆ #2736 | Overweight | $80.00→ $90.00+12.5% |
|
Aug 12
00:54 UTC
|
ASST
Strive
|
◎ Target | Mike Colonnese ★☆☆☆☆ #3029 | Buy | $37.00→ $36.00-2.7% |
|
Aug 12
00:54 UTC
|
ASPN
Aspen Aerogels
|
◎ Target | David Anderson ★★☆☆☆ #2285 | Underweight | $4.00→ $5.00+25.0% |
|
Aug 12
00:54 UTC
|
APLE
Apple Hospitality REIT
|
◎ Target | Jay Kornreich ★★★★☆ #795 | Overweight | $16.00→ $18.00+12.5% |
|
Aug 12
00:54 UTC
|
APEI
American Public Education
|
◎ Target | Eric Martinuzzi ★★★☆☆ #1779 | Buy | $62.00→ $64.00+3.2% |
|
Aug 12
00:54 UTC
|
APA
APA
|
◎ Target | Biju Perincheril not yet tracked | Positive | $45.00→ $47.00+4.4% |
|
Aug 12
00:54 UTC
|
AN
AutoNation
|
◎ Target | Bill Selesky ★★★☆☆ #1374 | Buy | $241.00→ $246.00+2.1% |
|
Aug 12
00:54 UTC
|
AMRZ
Amrize
|
◎ Target | Anthony Pettinari ★★★☆☆ #1043 | Buy | $66.00→ $58.00-12.1% |
|
Aug 12
00:54 UTC
|
AMPY
Amplify Energy
|
◎ Target | Subash Chandra ★★☆☆☆ #2649 | Buy | $11.00→ $9.00-18.2% |
|
Aug 12
00:54 UTC
|
ALS
Altius Minerals
|
◎ Target | firm only | C$60.00→ C$70.00+16.7% | |
|
Aug 12
00:54 UTC
|
ALMR
Alamar Biosciences
|
◎ Target | Daniel Arias ★★★★★ #28 | Buy | $28.00→ $32.00+14.3% |
|
Aug 12
00:54 UTC
|
ALMR
Alamar Biosciences
|
◎ Target | Casey Woodring ★★★★★ #11 | Overweight | $32.00→ $35.00+9.4% |
|
Aug 12
00:54 UTC
|
ALL
Allstate
|
◎ Target | Pablo Singzon ★★★★★ #177 | Overweight | $282.00→ $292.00+3.5% |
|
Aug 12
00:54 UTC
|
AIOT
PowerFleet
|
◎ Target | Anthony Stoss ★★☆☆☆ #2706 | Buy | $9.00→ $6.00-33.3% |
|
Aug 12
00:54 UTC
|
AIG
American International Group
|
◎ Target | Meyer Shields ★★★★★ #147 | Outperform | $95.00→ $96.00+1.1% |
|
Aug 12
00:54 UTC
|
AFL
Aflac
|
◎ Target | Pablo Singzon ★★★★★ #177 | Neutral | $117.00→ $116.00-0.9% |
|
Aug 12
00:54 UTC
|
AFL
Aflac
|
◎ Target | Ryan Krueger ★★★★★ #199 | Market Perform | $120.00→ $125.00+4.2% |
|
Aug 12
00:54 UTC
|
AFG
American Financial Group
|
◎ Target | Meyer Shields ★★★★★ #147 | Market Perform | $148.00→ $153.00+3.4% |
|
Aug 12
00:54 UTC
|
ADNT
Adient
|
◎ Target | Michael Ward ★★☆☆☆ #2438 | Buy | $33.00→ $29.00-12.1% |
|
Aug 12
00:54 UTC
|
ACM
AECOM
|
◎ Target | Andrew Wittmann ★★★★☆ #418 | Neutral | $87.00→ $73.00-16.1% |
|
Aug 12
00:54 UTC
|
ACGL
Arch Capital Group
|
◎ Target | Pablo Singzon ★★★★★ #177 | Neutral | $116.00→ $118.00+1.7% |
|
Aug 12
00:54 UTC
|
ABX
Barrick Gold
|
◎ Target | firm only | Outperform | C$58.00→ C$56.00-3.4% |
|
Aug 12
00:54 UTC
|
ABX
Barrick Gold
|
◎ Target | firm only | Sec→ r Perform | C$60.00→ C$57.00-5.0% |
|
Aug 12
00:54 UTC
|
ABX
Barrick Gold
|
◎ Target | firm only | Outperform | C$67.50→ C$70.00+3.7% |
|
Aug 12
00:54 UTC
|
ABCL
AbCellera Biologics
|
◎ Target | Robyn Kamaus not yet tracked | Buy | $12.00→ $30.00+150.0% |
|
Aug 12
00:54 UTC
|
ABBV
AbbVie
|
◎ Target | Navann Ty ★★☆☆☆ #2645 | Neutral | $218.00→ $247.00+13.3% |
|
Aug 12
00:54 UTC
|
AAON
AAON
|
◎ Target | Noah Kaye ★★★☆☆ #2148 | Outperform | $145.00→ $125.00-13.8% |
|
Aug 12
00:54 UTC
|
AAON
AAON
|
◎ Target | Timothy Wojs ★★★☆☆ #1958 | Outperform | $150.00→ $135.00-10.0% |
|
Aug 12
00:54 UTC
|
ZGN
Ermenegildo Zegna
|
↓ Downgrade | firm only | Neutral→ Underperform | $12.20 |
|
Aug 12
00:54 UTC
|
UAA
Under Armour
|
↓ Downgrade | Adrienne Yih ★★★☆☆ #1593 | Equal Weight→ Underweight | $5.00 |
|
Aug 12
00:54 UTC
|
TENX
Tenax Therapeutics
|
↓ Downgrade | firm only | Outperform→ In-Line | $5.00 |
|
Aug 12
00:54 UTC
|
ROOT
Root
|
↓ Downgrade | Andrew Andersen ★★★☆☆ #1930 | Buy→ Hold | $78.00→ $58.00-25.6% |
|
Aug 12
00:54 UTC
|
NABL
N-able
|
↓ Downgrade | Matthew Hedberg ★★★★☆ #425 | Outperform→ Sector Perform | $6.00→ $4.00-33.3% |
|
Aug 12
00:54 UTC
|
MNDY
monday.com
|
↓ Downgrade | Alex Zukin ★☆☆☆☆ #3134 | Outperform→ Peer Perform | |
|
Aug 12
00:54 UTC
|
HZO
MarineMax
|
↓ Downgrade | Brandon Rolle ★★☆☆☆ #2869 | Buy→ Hold | $53.00 |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.